Geron Corporation (GERN NASDAQ) stock market data APIs
$2.92
0.03(1%)
as of January 17, 2025
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
2.89
Open
2.92
Volume
8 638 K
High
2.985
Low
2.85
52 wk Range
1.64-5.34
Market Cap
1 747 M
Shares Outstanding
605 M
Revenue
29 480 K
EPS
-0.04
Beta
0.515
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 29 480 K
- EBITDA: -207 452 992
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
Royalty Pharma plc RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia Transaction increases Royalty Ph...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., October 17, 2024--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options t...
Is Geron Corporation (GERN) the Hottest Penny Stock to Invest in According to Hedge Funds?
In this article, we will look at the 8 Hot Penny Stocks To Invest In According to Hedge Funds. Let’s look at where Geron Corporation (GERN) stands against other hot penny stocks. Financial markets...
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
FOSTER CITY, Calif., October 15, 2024--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 fina...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
